MycobacteriumShigellaListeriaThe present disclosure relates generally to alpha helix mimetic structures and specifically to alpha helix mimetic structures that are inhibitors of catenin. The disclosure also relates to applications in the treatment of viral and infectious diseases including infection by HIV HPV HBV HSV and bacteria including and and pharmaceutical compositions comprising such alpha helix mimetic catenin inhibitors.